Vinh Duong, MD
Interventional Cardiology · Southaven, MSNPI 1285011643
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,730 of the $7,952 with a category attached, or 72.1%. 31 manufacturers reported payments, led by Penumbra, Inc. at 24.3% of the total. That places this record below the midpoint for interventional cardiology clinicians in MS, where the typical reported total is $7,952.
Across 179 payments — averaging $44.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$2K
- Abbott$2K
- Medtronic$865
- Abiomed$397
- Shockwave Medical, Inc$394
- Boston Scientific$365
- plus $2K from 25 others
What the payments were for
- Travel & lodging$2,22128%
- Food & beverage$5,73072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 11 | $1,929 |
| Abbott | 18 | $1,876 |
| Medtronic | 67 | $865 |
| Abiomed | 4 | $397 |
| Shockwave Medical, Inc | 5 | $394 |
| Boston Scientific | 9 | $365 |
| Philips North America LLC | 18 | $334 |
| ZOLL Circulation Inc | 2 | $276 |
| Livanova USA, Inc. | 2 | $199 |
| Merck | 10 | $196 |
| Amgen | 4 | $165 |
| Edwards Lifesciences | 1 | $133 |
| Heartflow, Inc. | 2 | $121 |
| Cardiovascular Systems Inc. | 1 | $120 |
| Boehringer Ingelheim | 3 | $111 |
| Cvrx, Inc. | 1 | $57 |
| AstraZeneca | 3 | $57 |
| Impulse Dynamics (USA) Inc. | 2 | $47 |
| Novo Nordisk | 2 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Stryker | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Cordis US CORP. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Terumo Medical Corporation | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$1,793
- OPTIS$1,147
- TherOx DS2 Console$276
- Catheter$276
- Downstream Cartridge$276
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$260
- COROFLOW$161
- LifeSPARC$157
- AVVIGO Guidance System$145
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$133
- Impella$128
- Diamondback Coronary$120
- RESOLUTE ONYX$116
- Repatha$112
- FFRct$107
How this compares
$7,952 in reported general payments places this provider in the 50th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $61,645 |
| JardianceEmpagliflozin | 46 | $48,098 |
| FarxigaDapagliflozin Propanediol | 16 | $12,179 |
| EntrestoSacubitril/Valsartan | 12 | $11,273 |
| BrilintaTicagrelor | 18 | $9,581 |
| ClopidogrelClopidogrel Bisulfate | 93 | $824 |
| Metoprolol Succinate | 59 | $462 |
| Rosuvastatin Calcium | 22 | $446 |
| Atorvastatin Calcium | 47 | $367 |
| Carvedilol | 60 | $319 |
| Metoprolol Tartrate | 48 | $274 |
| Losartan Potassium | 44 | $246 |
| Amlodipine Besylate | 42 | $236 |
| Furosemide | 46 | $195 |
| Cilostazol | 18 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $61,64576 claims |
| Boehringer IngelheimJardiance | $111 | $48,09846 claims |
| AstraZenecaFarxiga, Brilinta | $57 | $21,76034 claims |
| NovartisEntresto | $16 | $11,27312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in Southaven
- Jimmy SneedSouthaven$12K
- Amit MalhotraSouthaven$10K
- Lauren PiersallSouthaven$5K
- John WinscottJackson$482K
- William CrowderJackson$331K
- Foluso FakoredeCleveland$298K
- James BennettJackson$160K
- Abdul BahroFlowood$132K
- Brett BennettJackson$126K
- John KingColumbus$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.